← All diseases
Cancer
Lung cancer (small cell)
Do you want to receive a message when there is new research about Small Cell Lung Cancer (SCLC)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above every publication you see one sentence explaining what was studied — and you'll be notified as soon as there is new research about Small cell lung cancer. View what Premium costs.
Publications (2646)
- Adjuvant chemotherapy appears less effective in undernourished lung cancer patients as assessed by the controlling nutritional status score: a retrospective cohort study. (2026/02/28) ♡
- Deciphering immune heterogeneity in lung adenocarcinoma via machine learning-based Differential Phenotype Immune Score: TPX2 as a key biomarker for immunotherapy resistance. (2026/02/27) ♡
- Specific depletion of TIGIT(high) CD226(-) clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. (2026/02/24) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. [Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients with Leptomeningeal Metastases: A Randomized Controlled Trial]. (2026/02/20) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Stage IIIB ROS1-Positive NSCLC management: crizotinib + surgery + TCM achieves exceptionally prolonged PFS (a case report). (2026/02/16) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparison. (2026/02/13) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Compounds and monomeric active ingredients of resolving phlegm and removing stasis therapy (RPST) for the treatment of non-small cell lung cancer: A comprehensive review. (2026/02/10) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical outcomes and safety of continuous immunotherapy beyond progression in patients with extensive-stage small cell lung cancer: a retrospective real-world study. (2026/02/06) ♡
- The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer. (2026/02/05) ♡
- Impact of Baseline Nutritional Status, Psychological Health, Fatigue, and Insomnia on Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study. (2026/02/01) ♡
- Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy. (2026/02/01) ♡
- Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors. (2026/02/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non-small cell lung cancer. (2026/02/01) ♡
- The Prognostic Impact of C-Reactive Protein-Albumin-Lymphocyte Index (Cally Index) in Patients with Surgically Resected Non-Small-Cell Lung Cancer. (2026/02/01) ♡
- Threonyl-tRNA synthetase activates STAT3 by a nontranslational mechanism. (2026/02/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Late-onset isolated corticotrophin deficiency induced by pembrolizumab in a patient with non-small-cell lung carcinoma. (2026/02/01) ♡
- Utilizing "Delocalized Electron Sailing" Strategy to Modulate Eg Orbital Occupancy of Dual-Atom Piezo-Catalyst for Ultrasound-Enhanced Immunotherapy. (2026/02/01) ♡
- ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. (2026/02/01) ♡
- Multifunctional extracellular vesicles inhibiting autophagy ameliorate immunotherapy in non-small cell lung cancer. (2026/02/01) ♡
- Oblique-incidence reflectivity difference technology identifies the antiviral drug Ribavirin as an inhibitor of lung tumor progression by targeting AMPK signaling. (2026/02/01) ♡
- Efficacy and Safety of Different Types of Traditional Chinese Medicine Preparations Combined with EGFR-TKIs for Patients with Non-Small Cell Lung Cancer: A Network Meta-analysis. (2026/02/01) ♡
- Huaier Aqueous Extract Combined with Gefitinib Promotes ACSL4-Dependent Ferroptosis and Overcomes Gefitinib Resistance in Non-Small Cell Lung Cancer. (2026/02/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. From inhibition to regulation: serpins in health and disease. (2026/02/01) ♡
- Flavones and Aminoflavones Increase the Cytotoxicity of NK Cells in Human Non-Small Cell Lung Cancer. (2026/02/01) ♡
- Body Composition in Resectable Non-Small Cell Lung Cancer Patients With Preoperative Sarcopenia: A Propensity-Matched Analysis. (2026/02/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A comprehensive clinical trajectory of EGFR A763_Y764insFQEA-positive non-small cell lung cancer treated with fifth-line osimertinib following circulating tumor DNA-based detection: a case report. (2026/01/31) ♡
- Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio. (2026/01/31) ♡
- Exploring the mechanisms of Hu-gu-xiao-ji formula and its components for treatment on non-small cell lung cancer using UPLC-QTOF-MS/MS, network pharmacology, and experiments. (2026/01/30) ♡
- Wu-wei-zi decoction reshapes the tumor immune microenvironment by targeting the IL-6/CD73 axis in myeloid-derived suppressor cells to inhibit non-small cell lung cancer. (2026/01/30) ♡
- Phytochemical reactions and biological activities of a traditional thai herbal formula for asthma treatment: free radical scavenging and inhibition of lung cancer cell proliferation. (2026/01/30) ♡
- B cell phenotypes and antibody signatures associate with interpatient variation in the lung adenocarcinoma tumor microenvironment. (2026/01/28) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Plasmodium infection fully activates the immune system in peripheral blood and tumor microenvironment in a murine Lewis lung cancer model. (2026/01/28) ♡
- Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy. (2026/01/28) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Triple-positive non-small cell lung cancer harboring EGFR mutation, ALK rearrangement, and high PD-L1 expression: a case report and literature review. (2026/01/27) ♡
- Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis. (2026/01/27) ♡
- Application and safety analysis of paravertebral block with dezocine and ropivacaine in video-assisted thoracoscopic surgery for lung cancer. (2026/01/27) ♡
- Single-cell sequencing and network pharmacology coupled with molecular docking and experimental validation reveal the effects of YPFS on macrophages in stage I non-small cell lung cancer. (2026/01/27) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond. (2026/01/26) ♡
- TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. (2026/01/26) ♡
- Anti-angiogenesis effect of Baiying Juhua Decoction on the non-small cell lung cancer: integrating pharmacology, multi-machine learning and experimental investigation. (2026/01/24) ♡
- Impact of smoking on immune feature and prognosis in unresectable stage III anaplastic lymphoma kinase positive non-small-cell lung cancer. (2026/01/23) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Jiedu Xiaozhen Granules for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Mediated Skin Toxicity: Protocol for a Randomized Controlled Trial. (2026/01/22) ♡
- Factors associated with longer brain metastasis-free survival in limited-disease small-cell lung cancer who underwent concurrent chemoradiotherapy, a retrospective analysis. (2026/01/19) ♡
- Serine synthesis and transport mediate the synergistic and detoxifying effects of lienal peptides on cisplatin. (2026/01/16) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Complex Interplay of Empyema and Chylothorax: A Case Report With Nutritional and Clinical Implication. (2026/01/12) ♡
- Impact of pre-therapeutic fasting plasma glucose on survival outcomes in advanced non-small cell lung cancer patients. (2026/01/09) ♡
- Multimodal cell death induced by indirubin-3'-oxime through inhibition of Akt/mTOR axis in lung cancer cells. (2026/01/05) ♡
- Association Between Immunotherapy and Overall Survival in Malnourished Patients with Advanced Non-Small Cell Lung Cancer: A Nationwide Retrospective Cohort Study in Japan. (2026/01/01) ♡
- Advanced Lung Cancer Inflammation Index has Prognostic Impact in Stage I Non-Small Cell Lung Cancer: A Registry-Based Analysis of 934 Patients. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Bone metastases in NSCLC: Modern paradigms in management and supportive care. (2026/01/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.